Armstrong Fleming & Moore’s AstraZeneca AZN Stock Holding History

Armstrong Fleming & Moore’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Hold	1,383	–	–	0.09%	94
2026 Q1	$273K	Hold	1,383	–	–	0.12%	88
2025 Q4	$254K	Hold	1,383	–	–	0.12%	87
2025 Q3	$212K	Buy	+1,383	New	+$209K	0.1%	106
2024 Q4	–	Sell	-1,372	Closed	-$214K	–	96
2024 Q3	$214K	Buy	1,372 +3	+0.2%	+$484	0.12%	95
2024 Q2	$213K	Buy	+1,369	New	+$206K	0.14%	89

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Armstrong Fleming & Moore's AZN Position: Q2 2026 in Review

Armstrong Fleming & Moore held its AstraZeneca (AZN) position steady in Q2 2026 at 1,383 shares worth $262K. The position accounts for 0.09% of the portfolio, ranked #94.

Armstrong Fleming & Moore first reported a position in AZN in Q2 2024 and has held it in 6 quarters since. The position peaked at $273K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Armstrong Fleming & Moore held 1,383 shares of AstraZeneca worth $262K as of Q2 2026.
Armstrong Fleming & Moore left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.09% of Armstrong Fleming & Moore's portfolio in Q2 2026, its #94 holding.
Armstrong Fleming & Moore first reported a position in AstraZeneca in Q2 2024 and has held it in 6 quarters since.
Armstrong Fleming & Moore's AstraZeneca position peaked at $273K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.